CAREL LE ROUX
Professor Carel le Roux graduated from medical school in Pretoria South Africa, completed his specialist training in metabolic medicine at St Bartholomew’s Hospitals and the Hammersmith Hospitals. He obtained his PhD from Imperial College London where he later took up a faculty position. He moved to University College Dublin for the Chair in Chemical Pathology and Metabolic Medicine and he is now a Director of the Metabolic Medicine Group. He also holds the position of Professor of Metabolic Medicine at Ulster University and Extra-ordinary Professor of Chemical Pathology at University of Pretoria. He currently coordinates an Innovative Medicine Initiative project on obesity. He previously received the Irish Research Council Researcher of the Year award, a President of Ireland Young Researcher Award, the Irish Research Council Laureate Award, a Clinician Scientist Award from the National Institute Health Research in the UK, and a Wellcome Trust Clinical Research Fellowship for his work on how the gut talks to the brain.
Check the activity agenda
Wednesday, June 26, 2024
• Room 4 - Peter Kopelman
10:00-11:30
SYMPOSIUM: SOPHIA ECO2024 - STRATIFICATION OF OBESITY PHENOTYPES TO OPTIMIZE FUTURE THERAPY (SOPHIA)
The objectives of SOPHIA, predictors of risk (Obesity clusters) and predictors of response (Bariatric surgery trajectory tool)
Q&A
Obesity in patients with type1 diabetes
The patient voice in SOPHIA
Q&A
Coordinator: Carel Le Roux (Ireland)
The objectives of SOPHIA, predictors of risk (Obesity clusters) and predictors of response (Bariatric surgery trajectory tool)
Speaker: Carel Le Roux (Ireland)
Q&A
Obesity in patients with type1 diabetes
Speaker: Ebaa Al Ozairi (Kuwait)
The patient voice in SOPHIA
Speaker: Werd Al-najim (Ireland)
Q&A
• Room 3+4 - Bernard Jeanrenaud
14:15-15:45
SESSION: THE GOLDEN AGE IN OBESITY PHARMACOTHERAPY
Bridging the gap between clinical and surgical treatments: what have we reached so far?
Future poli-agonists for the treatment of obesity and metabolic diseases
“Novel targets – appetite and beyond – Are we getting there?
Discussion
Coordinator: Louise Baur (Australia)
Bridging the gap between clinical and surgical treatments: what have we reached so far?
Speaker: Walmir Coutinho (RJ)
Future poli-agonists for the treatment of obesity and metabolic diseases
Speaker: Carel Le Roux (Ireland)
“Novel targets – appetite and beyond – Are we getting there?
Speaker: Donna Ryan (United States)
Discussion
Thursday, June 27, 2024
• Room 1 - Alfredo Halpern
08:00-09:30
SESSION: THE LANCET COMMISSION ON THE DEFINITION OF CLINICAL OBESITY: BACKGROUND, OBJECTIVES AND PROGRESS REPORT
Background to the Lancet Commission
The pathophysiology of obesity as a discrete disease
BMI as a clinical and epidemiological instrument
BMI and obesity considerations in paediatric populations
Discussion
Coordinator: Eric Ravussin (United States)
Background to the Lancet Commission
Speaker: Ricardo Vitor Cohen (SP)
The pathophysiology of obesity as a discrete disease
Speaker: Carel Le Roux (Ireland)
BMI as a clinical and epidemiological instrument
Speaker: Ricardo Vitor Cohen (SP)
BMI and obesity considerations in paediatric populations
Speaker: Louise Baur (Australia)
Discussion
• Room 5 - Phillip James
14:00-15:30
SESSION: OBESITY AND TYPE 1 DIABETES
Abstracts - 128844: DOES OBESITY CONFER A DIFFERING RISK ON PREGNANCY OUTCOMES IN WOMEN WITH TYPE 1 DIABETES VERSUS TYPE 2 DIABETES? NOVEL DATA FROM AN AUSTRALIAN RETROSPECTIVE STUDY (2010-2019) COMPARING PREGNANCY OUTCOMES STRATIFIED BY BMI CATEGORY IN WOMEN WITH PREGE - Presenter: Xi May Zhen
Size of the problem and using nutrition therapy and exercise therapy for people living with obesity and type 1 diabetes
Pharmacotherapy for people living with obesity and type 1 diabetes
Surgical therapy for people living with obesity and type 1 diabetes
Discussion
Coordinator: Roberto Zagury (RJ)
Coordinator: Rodrigo Nunes Lamounier (MG)
Abstracts - 128844: DOES OBESITY CONFER A DIFFERING RISK ON PREGNANCY OUTCOMES IN WOMEN WITH TYPE 1 DIABETES VERSUS TYPE 2 DIABETES? NOVEL DATA FROM AN AUSTRALIAN RETROSPECTIVE STUDY (2010-2019) COMPARING PREGNANCY OUTCOMES STRATIFIED BY BMI CATEGORY IN WOMEN WITH PREGE - Presenter: Xi May Zhen
Size of the problem and using nutrition therapy and exercise therapy for people living with obesity and type 1 diabetes
Speaker: Carel Le Roux (Ireland)
Pharmacotherapy for people living with obesity and type 1 diabetes
Speaker: Ebaa Al Ozairi (Kuwait)
Surgical therapy for people living with obesity and type 1 diabetes
Speaker: Ricardo Vitor Cohen (SP)
Discussion
Friday, June 28, 2024
• Room 1 - Alfredo Halpern
11:00-12:30
SYMPOSIUM: IFSO-WOF THE COMBINATION OF DRUGS AND SURGERY
Long term outcomes and safety of metabolic surgery
Will efficacious modern pharmacotherapy replace metabolic surgery?
Improving the results of MS adding medical treatment
What can internists expect after sustained weight loss with pharmacotherapy: lessons learned from bariatric surgery
Uptake of obesity treatments: what do patients think
Discussion
Coordinator: Ebaa Al Ozairi (Kuwait)
Coordinator: Ricardo Vitor Cohen (SP)
Long term outcomes and safety of metabolic surgery
Speaker: Ricardo Vitor Cohen (SP)
Will efficacious modern pharmacotherapy replace metabolic surgery?
Speaker: Ebaa Al Ozairi (Kuwait)
Improving the results of MS adding medical treatment
Speaker: Carel Le Roux (Ireland)
What can internists expect after sustained weight loss with pharmacotherapy: lessons learned from bariatric surgery
Speaker: Carlos Schiavon (SP)
Uptake of obesity treatments: what do patients think
Speaker: Ricardo Vitor Cohen (SP)
Discussion
Venue
Centro de Convenções Frei Caneca
R. Frei Caneca, 569 - Bela Vista,
São Paulo - SP, 01307-001
R. Frei Caneca, 569 - Bela Vista,
São Paulo - SP, 01307-001
website ACCOMMODATION
PROMOTED BY
MANAGEMENT
Tourism Agency
DIAMOND SPONSOR
GOLD SPONSOR
BRONZE SPONSOR
SPONSOR
